529 completed, 103 recruiting, 76 terminated, 72 unknown. 877 Phase 2, 119 Phase 3, 118 Phase 1.
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Health Coaching and Veteran Reintegration Health Coaching, Enhanced treatment as usual - Reintegration Into Civilian Life | Phase 2 | Not yet recruiting | VA Office of Research and Development | 398 | 2027-07-01 | 2026-07-24 |
| Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment Sildenafil - Cancer | Phase 2 / Phase 3 | Not yet recruiting | The University of Texas Medical Branch, Galveston | 30 | 2027-06-15 | 2026-05-11 |
| Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay Esketamine, Midazolam (Intravenous) - Suicidal Ideation, Suicidal Behavior | Phase 2 | Not yet recruiting | University of Sao Paulo | 106 | 2027-04-30 | 2026-10-22 |
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE) Exercise, Duloxetine, Placebo - Knee Osteoarthritis, Pain | Phase 2 | Not yet recruiting | VA Office of Research and Development | 102 | 2027-03-01 | 2026-06-16 |
| Reducing Firearm Suicide Among Veterans: Evaluating the Effectiveness of Peer-Delivered Lethal Means Counseling Peer Engagement and Exploration of Responsibility and Safety, Active Control - Suicide, Secure Firearm Storage | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 100 | 2027-02-01 | 2026-10-26 |
| Lisdexamfetamine For the Treatment of Conduct Disorder in Children Lidexamfetamine - Conduct Disorder | Phase 2 | Not yet recruiting | Orygen | 30 | 2027-02-01 | 2026-11-06 |
| Psilocybin FCR Early-Stage Breast Cancer Psilocybin 25 mg, Psilocybin 5 mg - Early-stage Breast Cancer, Fear of Cancer Recurrence | Phase 2 | Not yet recruiting | NYU Langone Health | 100 | 2027-01-02 | 2026-11-02 |
| Psilocybin for Depression in Veterans Psilocybin, modafinil, zolpidem - Major Depression | Phase 2 | Not yet recruiting | VA Office of Research and Development | 150 | 2027-01-01 | 2026-10-26 |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | University of New Mexico | 150 | 2026-12-31 | 2026-10-30 |
| Allopregnanolone in Chronic Complex Traumatic Brain Injury Placebo, Allopregnanolone - Traumatic Brain Injury (TBI) | Phase 2 | Not yet recruiting | VA Office of Research and Development | 132 | 2026-12-01 | 2026-10-19 |
| Peer Support for Family Caregivers of Older Adults Living With Dementia Peer Support, Usual Care - Caregiver Burden, Caregiver Burnout | Phase 2 | Not yet recruiting | Ohio State University | 344 | 2026-12-01 | 2026-10-14 |
| Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression Ketamine hydrochloride injection - Treatment Resistant Depression (TRD), Chronic Pain | Phase 2 | Not yet recruiting | University of Rochester | 25 | 2026-12-01 | 2026-09-24 |
| Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Tocilizumab, Placebo, Whole-Body Hyperthermia - Major Depressive Disorder | Phase 2 | Suspended | Massachusetts General Hospital | 35 | 2026-12-01 | 2025-11-13 |
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response Ketamine - Epilepsy, Depressive Symptoms | Phase 2 | Not yet recruiting | Emory University | 37 | 2026-12-01 | 2026-08-17 |
| Retreat-Based Program for Violence-Exposed Women Veterans GRIT, GRI - Suicide Prevention | Phase 2 | Not yet recruiting | VA Office of Research and Development | 48 | 2026-12-01 | 2026-07-31 |
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome SRX246, Placebo - Aggressive Behavior in Fragile X Syndome | Phase 2 | Not yet recruiting | Azevan Pharmaceuticals | 80 | 2026-12-01 | 2026-10-30 |
| Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome N-acetyl cysteine, Placebo - Cornelia de Lange Syndrome | Phase 2 | Not yet recruiting | Johns Hopkins University | 10 | 2026-11-01 | 2026-08-14 |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety CYB003, Placebo - Depression, Anxiety | Phase 2 | Recruiting | Ohio State University | 40 | 2026-11-01 | 2026-10-20 |
Showing 20 of 877. Sign in to see all of them.
Depression (666) · Depressive Disorder, Major (213) · Anxiety Disorders (125) · Depressive Disorder (72) · Bipolar Disorder (62) · Psychomotor Agitation (44) · Mood Disorders (42) · Aggression (40) · Depressive Disorder, Treatment-Resistant (40) · Suicidal Ideation (39) · Suicide (34) · Stress Disorders, Post-Traumatic (32) · Mental Disorders (28) · Alzheimer Disease (27) · Dementia (27)
Behavior (871) · Mental Disorders (550) · Mood Disorders (270) · Pathological Conditions, Signs and Symptoms (204) · Depressive Disorder (192) · Signs and Symptoms (172) · Nervous System Diseases (165) · Neurologic Manifestations (130) · Central Nervous System Diseases (82) · Brain Diseases (79) · Neurobehavioral Manifestations (79) · Aberrant Motor Behavior in Dementia (73) · Self-Injurious Behavior (68) · Bipolar and Related Disorders (62)
Ketamine (56) · Psilocybin (35) · Cognitive Behavioral Therapy (26) · Escitalopram (22) · Sertraline (21) · Therapeutics (19) · Transcranial Magnetic Stimulation (17) · Fluoxetine (15) · Midazolam (13) · Citalopram (12) · Duloxetine Hydrochloride (12) · Exercise (11) · Dexmedetomidine (10) · Sodium Chloride (10) · Transcranial Direct Current Stimulation (10)
National Institute of Mental Health (NIMH) (26) · Massachusetts General Hospital (21) · New York State Psychiatric Institute (14) · VA Office of Research and Development (14) · Johns Hopkins University (11) · Medical University of South Carolina (11) · University of Chicago (11) · Icahn School of Medicine at Mount Sinai (10) · The University of New South Wales (10) · University of Washington (10) · Washington University School of Medicine (9) · Yale University (9) · US Department of Veterans Affairs (8) · University of California, Los Angeles (8) · University of California, San Diego (8)
United States (568) · Canada (66) · United Kingdom (35) · Australia (29) · Germany (25) · China (23) · France (23) · Spain (23) · Poland (22) · Brazil (18) · Netherlands (18) · Bulgaria (14) · Sweden (14) · Czechia (13) · Norway (12)
Carlos A Zarate, M.D. (8) · Maurizio Fava, MD (8) · BioXcel MM, MD (4) · Jon E Grant, MD, JD, MPH (4) · Andrew A Nierenberg, MD (3) · Gregory A Harshfield, PhD (3) · Peter Nagele, MD, MSc (3) · Alessandra Gorgulho, MD, MSc (2)
PMID 34510411, PMID 32364251, PMID 33677832, PMID 33884617, PMID 20732631, PMID 22296967, PMID 23146246, PMID 24126931, PMID 27355533, PMID 31969269, PMID 32368793, PMID 32785636, PMID 34532852, PMID 34817851, PMID 35092868, PMID 37585253, PMID 37651119, PMID 39955416, PMID 40398609, PMID 41545765, PMID 42304135, PMID 42477489, PMID 10843272, PMID 12534758, PMID 12719501, PMID 15154020, PMID 15213794, PMID 15365580, PMID 15556826, PMID 15583741, PMID 15890495, PMID 15913920, PMID 15943960, PMID 15978266, PMID 16173913, PMID 16319710, PMID 16390366, PMID 16491981, PMID 16630205, PMID 16676910, PMID 16894061, PMID 17013851, PMID 17068314, PMID 17227604, PMID 18025870, PMID 18314433, PMID 18469236, PMID 18501061, PMID 18652095, PMID 18671864
2023 (6), 2016 (5), 2014 (4), 2008 (3), 2025 (3), 2015 (2), 2018 (2), 271201100006I-0-27100007-1 (2), P50DA009236 (2), R33MH122464 (2), U10CA081851 (2), 1IK2CX002877-01A1 (1), 1UG3DA066242-01 (1), 2009 (1), 2017 (1)